Lanean...
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance
INTRODUCTION: HER2 overexpression/amplification is identified in up to 40% of uterine serous carcinomas (USC) and 10% of ovarian serous carcinomas (OSC). However, clinical trials using various HER2-targeted agents failed to show significant responses. FDA-approved HER2 assays target only the protein...
Gorde:
| Argitaratua izan da: | Gynecol Oncol |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5941302/ https://ncbi.nlm.nih.gov/pubmed/28196634 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2017.02.002 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|